Demystifying Moderna: Insights From 11 Analyst Reviews
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Moderna (NASDAQ:MRNA) have shown a negative shift in sentiment over the past quarter, with a decrease in the average 12-month price target by 8.19%. Recent evaluations from 11 analysts reveal a mix of bullish, somewhat bullish, and indifferent ratings, with no bearish sentiments. Key analysts from firms like JP Morgan, Deutsche Bank, and Goldman Sachs have lowered their price targets, reflecting concerns over Moderna's financial performance, including a significant revenue decline and negative net margins.
August 15, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have shown a negative shift in sentiment for Moderna, with a decrease in the average 12-month price target by 8.19%. Key analysts from major firms have lowered their price targets, reflecting concerns over the company's financial performance, including a significant revenue decline and negative net margins.
The decrease in the average price target by 8.19% and the lowering of price targets by key analysts from major firms indicate a negative sentiment towards Moderna's stock. This is further supported by the company's financial challenges, including a significant revenue decline and negative net margins.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100